Bayer Receives Fast Track Designation from FDA for asundexian to Prevent Thrombosis in Patients with Atrial Fibrillation
May 16, 2023: Bayer announced that the FDA has granted fast-track status to asundexian, an oral factor 11a inhibitor in clinical development as a potential treatment for stroke and systemic embolism in patients with atrial fibrillation.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations